Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

• Main Authors: Christoph Fraune (Author), Luisa Harms (Author), Franziska Büscheck (Author), Doris Höflmayer (Author), Maria Christina Tsourlakis (Author), Till S. Clauditz (Author), Ronald Simon (Author), Katharina Möller (Author), Andreas M. Luebke (Author), Christina Möller-Koop (Author), Stefan Steurer (Author), Claudia Hube-Magg (Author), Guido Sauter (Author), Sören Weidemann (Author), Patrick Lebok (Author), David Dum (Author), Simon Kind (Author), Sarah Minner (Author), Jakob R. Izbicki (Author), Thorsten Schlomm (Author), Hartwig Huland (Author), Hans Heinzer (Author), Eike Burandt (Author), Alexander Haese (Author), Markus Graefen (Author), Cornelia Schroeder (Author)
• Format: Book
• Published: BMC, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background TFAP2D is a transcription factor important for modulating gene expression in embryogenesis. Its expression and prognostic role in prostate cancer has not been evaluated. Methods Therefore, a tissue microarray containing 17,747 prostate cancer specimens with associated pathologica...